Fairvalue-Calculator Fairvalue-Calculator
EN DE

EMVision Medical Devices Ltd (EMV) Fair Value & Analysis

Healthcare · AU · Market cap A$152M

PriceA$1.56
Fair ValueA$0.4500
Upside-71.2%
Quality95/100
Evidence: Low Range A$0.3400 – A$0.5600

Fair value as of: Jun 24, 2026

Analysis

EMVision Medical Devices Ltd (EMV) currently trades at A$1.56, while our model-based Fair Value estimate is A$0.4500 — implying the stock looks roughly 71.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non-invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is EMVision Medical Devices Ltd (EMV) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.4500 versus a price of A$1.56 — about −71% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EMV?
Our 21-model fair value for EMVision Medical Devices Ltd is A$0.4500 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$1.56.
What is the quality score of EMV?
EMVision Medical Devices Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.